title: Phase II study of S-1 and docetaxel for previously treated patients with locally advanced or metastatic non-small cell lung cancer.
abstract: OBJECTIVE
  The purpose of the present phase II study was to evaluate both the efficacy and toxicity of the combination of S-1 and docetaxel in previously treated patients with locally advanced or metastatic non-small cell lung cancer.
  
  
  METHODS
  Thirty-eight previously treated patients with non-small cell lung cancer were treated with S-1 (80 mg/m(2), days 1-14, oral) and docetaxel (40 mg/m(2), day 1, intravenous) every 3 weeks.
  
  
  RESULTS
  No complete response was observed, and seven patients had a partial response, yielding an overall response rate of 18.4% (95% CI, 7.7-34.3%). The median overall survival time and 1-year overall survival rate were 16.1 months and 60%, respectively. The median progression-free survival time was 4.4 months. Myelosuppression was the main toxicity with grade 3 or 4 neutropenia and leukopenia in 50 and 21%, respectively. There was no irreversible toxicity in this study.
  
  
  CONCLUSIONS
  The combination of S-1 and docetaxel is well tolerable and has substantial activity for patients with locally advanced or metastatic non-small cell lung cancer. A phase III trial comparing docetaxel with or without S-1 would warrant further investigation.
authors.affiliation: Outpatient Oncology Unit, Kyoto University Hospital, Kyoto, Japan, kazuhiro@kuhp.kyoto-u.ac.jp.
authors.forename: Kazuhiro
authors.initials: K
authors.lastname: Yanagihara
authors.forename: Kenichi
authors.initials: K
authors.lastname: Yoshimura
authors.forename: Miyuki
authors.initials: M
authors.lastname: Niimi
authors.forename: Hiroyasu
authors.initials: H
authors.lastname: Yasuda
authors.forename: Takahiko
authors.initials: T
authors.lastname: Sasaki
authors.forename: Takafumi
authors.initials: T
authors.lastname: Nishimura
authors.forename: Hiroshi
authors.initials: H
authors.lastname: Ishiguro
authors.forename: Shigemi
authors.initials: S
authors.lastname: Matsumoto
authors.forename: Toshiyuki
authors.initials: T
authors.lastname: Kitano
authors.forename: Masashi
authors.initials: M
authors.lastname: Kanai
authors.forename: Akiko
authors.initials: A
authors.lastname: Misawa
authors.forename: Harue
authors.initials: H
authors.lastname: Tada
authors.forename: Satoshi
authors.initials: S
authors.lastname: Teramukai
authors.forename: Tadashi
authors.initials: T
authors.lastname: Mio
authors.forename: Masanori
authors.initials: M
authors.lastname: Fukushima
mesh_terms: D000328:Adult; D000368:Aged; D000971:Antineoplastic Combined Chemotherapy Protocols / Q000009:adverse effects / Q000627:therapeutic use*; D002289:Carcinoma, Non-Small-Cell Lung / Q000188:drug therapy* / Q000473:pathology; D018572:Disease-Free Survival; D000077143:Docetaxel; D004338:Drug Combinations; D005260:Female; D005500:Follow-Up Studies; D006801:Humans; D007970:Leukopenia / Q000139:chemically induced; D008175:Lung Neoplasms / Q000188:drug therapy* / Q000473:pathology; D008297:Male; D008875:Middle Aged; D009362:Neoplasm Metastasis; D009503:Neutropenia / Q000139:chemically induced; D010094:Oxonic Acid / Q000008:administration & dosage; D015996:Survival Rate; D043823:Taxoids / Q000008:administration & dosage; D005641:Tegafur / Q000008:administration & dosage; D016896:Treatment Outcome
chemical_list: D004338:Drug Combinations; D043823:Taxoids; C079198:S 1 (combination); D005641:Tegafur; D000077143:Docetaxel; D010094:Oxonic Acid